These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29304561)

  • 1. Cross Talk Between Cellular Redox State and the Antiapoptotic Protein Bcl-2.
    Pohl SÖ; Agostino M; Dharmarajan A; Pervaiz S
    Antioxid Redox Signal; 2018 Nov; 29(13):1215-1236. PubMed ID: 29304561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2.
    Krishna S; Low IC; Pervaiz S
    Biochem J; 2011 May; 435(3):545-51. PubMed ID: 21486225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
    Yu L; Liu S
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells.
    Low IC; Kang J; Pervaiz S
    Antioxid Redox Signal; 2011 Dec; 15(12):2975-87. PubMed ID: 21574773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-oxidant and pro-oxidant dichotomy of Bcl-2.
    Yee YH; Chong SJ; Pervaiz S
    Biol Chem; 2016 Jul; 397(7):585-93. PubMed ID: 27060742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
    Goldsmith KC; Hogarty MD
    Curr Opin Investig Drugs; 2009 Jun; 10(6):559-71. PubMed ID: 19513945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison.
    Chong SJF; Lai JXH; Eu JQ; Bellot GL; Pervaiz S
    Antioxid Redox Signal; 2018 Dec; 29(16):1553-1588. PubMed ID: 29186971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells.
    Bettaieb A; Dubrez-Daloz L; Launay S; Plenchette S; Rébé C; Cathelin S; Solary E
    Curr Med Chem Anticancer Agents; 2003 Jul; 3(4):307-18. PubMed ID: 12769775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.
    Letai A
    Expert Opin Biol Ther; 2003 Apr; 3(2):293-304. PubMed ID: 12662143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
    Hartman ML; Czyz M
    Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bcl-2 family: structures, interactions and targets for drug discovery.
    Kvansakul M; Hinds MG
    Apoptosis; 2015 Feb; 20(2):136-50. PubMed ID: 25398535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy.
    Tomek M; Akiyama T; Dass CR
    J Pharm Pharmacol; 2012 Dec; 64(12):1695-702. PubMed ID: 23146031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor intracellular redox status and drug resistance--serendipity or a causal relationship?
    Pervaiz S; Clement MV
    Curr Pharm Des; 2004; 10(16):1969-77. PubMed ID: 15180532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BCL-2-like Proteins to Kill Cancer Cells.
    Cory S; Roberts AW; Colman PM; Adams JM
    Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BCL-2 protein family, BH3-mimetics and cancer therapy.
    Delbridge AR; Strasser A
    Cell Death Differ; 2015 Jul; 22(7):1071-80. PubMed ID: 25952548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New dimension in therapeutic targeting of BCL-2 family proteins.
    Besbes S; Mirshahi M; Pocard M; Billard C
    Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH4 domain of Bcl-2 as a novel target for cancer therapy.
    Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
    Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
    Sarosiek KA; Letai A
    FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
    Yap JL; Chen L; Lanning ME; Fletcher S
    J Med Chem; 2017 Feb; 60(3):821-838. PubMed ID: 27749061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.